Welcome, Guest. Please login or register.
July 15, 2024, 12:51:52 pm

Login with username, password and session length

  • Total Posts: 55130
  • Total Topics: 4851
  • Online Today: 209
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 44
Total: 44


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: New treatment?  (Read 4887 times)

0 Members and 1 Guest are viewing this topic.

Offline julu49

  • Member
  • Posts: 63
New treatment?
« on: October 08, 2015, 09:41:24 pm »
I just read this, and am sending on a little clip. It looks like Gilead is continuing to find better and better hep c drugs

McMahon Publications Anesthesiology Gastroenterology General Surgery Infectious Disease Oncology Pain Medicine Pharmacy Specialty Pharmacy CMEZone 


Specialty Pharmacy Continuum 

advanced search     


Login ID  Register | Forgot Password
Password   Remember me   




Medical Education

Digital Editions






Contact Info

Web Only

printer friendly  |    email this article

Gilead Close to Pan-Genotypic HCV Drug Submission

by Gina Shaw

Gilead has released top-line data from the four Phase III ASTRAL studies that combined its blockbuster hepatitis C drug sofosbuvir (Sovaldi) and the investigational agent velpatasvirā€”and the result is a knockout.


In a trial including 624 patients with any of the six strains of hepatitis C virus (HCV), the combination produced a sustained virologic response (SVR) after 12 weeks of therapy in 99% of cases.


In the ASTRAL-1, ASTRAL-2 and ASTRAL-3 trials, a total of 1,035 patients with HCV genotypes 1 to 6 infec-tion received 12 weeks of the sofosbuvir/velpatasvir combination (SOF/VEL). Twenty-one percent of the patients in this group had compensated cirrhosis; 28% had failed prior treatments.
 - See more at: http://www.specialtypharmacycontinuum.com/ViewArticle.aspx?ses=ogst&d=Web+Only&d_id=530&i=October+2015&i_id=1230&a_id=33970#sthash.INJV9ieX.dpuf


© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.